NCT00858637
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
See it on ClinicalTrials.gov ↗259 people
46.3%
53.7%
120 womenmiddle line = equal numbers139 men
- Phase
- PHASE3
- Paid for by
- Tanabe Pharma Corporation
- Finished
- 2010-03
- Health conditions
- Chronic Kidney Disease
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 53.8 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“If Female and of child-bearing potential, have a negative serum pregnancy test”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Male subjects must agree to use appropriate contraception”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Biliary obstruction or proven liver dysfunction”
Study titles and rules are shown in their original English.